RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics for RAS-driven cancers, today announced it will present Phase 1 clinical data on QTX3034 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston, Mass. QTX3034 is an oral, G12D-preferring, multi-KRAS inhibitor currently being evaluated in a Phase 1 clinical trial in patients with KRASG12D mutant solid tumors.AACR-NCI-EORTC presentation information:Title: A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors with KRASG12D mutationDate and Time: Friday, October 24, 2025; 11:45 am – 12:15 pmSession Name: Spotlight on Proffered Papers 2: Clinical Advances in Targeting KRASPresenter: Ignacio Garrido-Laguna, MD, PHD, MBA, Huntsman ...Full story available on Benzinga.com